MX2014003643A - Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e] azulenos como antagonistas de v1a. - Google Patents
Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e] azulenos como antagonistas de v1a.Info
- Publication number
- MX2014003643A MX2014003643A MX2014003643A MX2014003643A MX2014003643A MX 2014003643 A MX2014003643 A MX 2014003643A MX 2014003643 A MX2014003643 A MX 2014003643A MX 2014003643 A MX2014003643 A MX 2014003643A MX 2014003643 A MX2014003643 A MX 2014003643A
- Authority
- MX
- Mexico
- Prior art keywords
- triaza
- oxa
- benzo
- antagonists
- receptor
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 2
- 150000001545 azulenes Chemical class 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 206010001488 Aggression Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 206010029164 Nephrotic syndrome Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000012761 aggressive behavior Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona 4H,6H-5-oxa-2,3,10b-triaza-benzo [e]azulenos, que actúan como moduladores del receptor de la V1a y en particular como antagonistas del receptor de la V1a, su obtención, composiciones farmacéuticas que los contienen y su utilización como medicamentos. Los compuestos activos de la presente invención son útiles como agentes terapéuticos que actúan a nivel periférico y central en estados patológicos tales como la dismenorrea, disfunción sexual masculina y femenina, hipertensión, fallo cardíaco crónico, secreción inapropiada de vasopresina, cirrosis hepática, síndrome nefrótico, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos del espectro autista, esquizofrenia y conducta agresiva.(ver fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182796 | 2011-09-26 | ||
| PCT/EP2012/068721 WO2013045373A1 (en) | 2011-09-26 | 2012-09-24 | Oxy-cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014003643A true MX2014003643A (es) | 2014-04-30 |
Family
ID=46881068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014003643A MX2014003643A (es) | 2011-09-26 | 2012-09-24 | Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e] azulenos como antagonistas de v1a. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8828989B2 (es) |
| EP (1) | EP2760871B1 (es) |
| JP (1) | JP5909554B2 (es) |
| KR (1) | KR101682777B1 (es) |
| CN (1) | CN103827121B (es) |
| AR (1) | AR087999A1 (es) |
| AU (1) | AU2012314593B2 (es) |
| BR (1) | BR112014006945A2 (es) |
| CA (1) | CA2844581A1 (es) |
| CL (1) | CL2014000717A1 (es) |
| CO (1) | CO6870036A2 (es) |
| CR (1) | CR20140092A (es) |
| EA (1) | EA024990B1 (es) |
| EC (1) | ECSP14013271A (es) |
| IN (1) | IN2014CN02169A (es) |
| MA (1) | MA35535B1 (es) |
| MX (1) | MX2014003643A (es) |
| PE (1) | PE20141397A1 (es) |
| PH (1) | PH12014500582A1 (es) |
| SG (1) | SG2014010607A (es) |
| TW (1) | TWI553013B (es) |
| UA (1) | UA111623C2 (es) |
| WO (1) | WO2013045373A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116194441A (zh) * | 2020-07-23 | 2023-05-30 | 豪夫迈·罗氏有限公司 | 作为加压素受体v1 a拮抗剂的环己基取代的三唑 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE249465T1 (de) | 1999-01-19 | 2003-09-15 | Ortho Mcneil Pharm Inc | Tricyclische benzodiazepine als vasopressin antagonisten |
| US6765004B1 (en) | 1999-06-17 | 2004-07-20 | Ortho-Mcneil Pharmaceutical, Inc. | Indoloazepines as vasopressin receptor antagonists |
| GB0303852D0 (en) * | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| US7119088B2 (en) | 2003-02-19 | 2006-10-10 | Pfizer Inc. | Triazole compounds useful in therapy |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| BRPI0514458A (pt) * | 2004-08-25 | 2008-06-10 | Pfizer | triazolbenzodiazepinas e seu uso como antagonistas de vasopressina |
| EP2358714B1 (en) | 2008-11-18 | 2012-08-01 | F. Hoffmann-La Roche AG | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| MY150837A (en) | 2008-11-28 | 2014-02-28 | Hoffmann La Roche | Arylcyclohexylethers of dihydrotetraazabenzoazulenes for use as vasopressin via receptor antagonists |
-
2012
- 2012-08-23 US US13/592,493 patent/US8828989B2/en active Active
- 2012-09-24 KR KR1020147010783A patent/KR101682777B1/ko not_active Expired - Fee Related
- 2012-09-24 IN IN2169CHN2014 patent/IN2014CN02169A/en unknown
- 2012-09-24 JP JP2014532331A patent/JP5909554B2/ja not_active Expired - Fee Related
- 2012-09-24 BR BR112014006945A patent/BR112014006945A2/pt not_active IP Right Cessation
- 2012-09-24 CA CA2844581A patent/CA2844581A1/en not_active Abandoned
- 2012-09-24 AU AU2012314593A patent/AU2012314593B2/en not_active Ceased
- 2012-09-24 SG SG2014010607A patent/SG2014010607A/en unknown
- 2012-09-24 EA EA201490558A patent/EA024990B1/ru not_active IP Right Cessation
- 2012-09-24 PH PH1/2014/500582A patent/PH12014500582A1/en unknown
- 2012-09-24 WO PCT/EP2012/068721 patent/WO2013045373A1/en not_active Ceased
- 2012-09-24 PE PE2014000394A patent/PE20141397A1/es not_active Application Discontinuation
- 2012-09-24 CN CN201280046689.0A patent/CN103827121B/zh not_active Expired - Fee Related
- 2012-09-24 EP EP12761740.5A patent/EP2760871B1/en active Active
- 2012-09-24 MX MX2014003643A patent/MX2014003643A/es unknown
- 2012-09-24 UA UAA201403611A patent/UA111623C2/uk unknown
- 2012-09-25 AR ARP120103514A patent/AR087999A1/es unknown
- 2012-09-25 TW TW101135168A patent/TWI553013B/zh not_active IP Right Cessation
-
2014
- 2014-01-31 CO CO14020668A patent/CO6870036A2/es not_active Application Discontinuation
- 2014-02-26 CR CR20140092A patent/CR20140092A/es unknown
- 2014-03-24 CL CL2014000717A patent/CL2014000717A1/es unknown
- 2014-03-26 EC ECSP14013271 patent/ECSP14013271A/es unknown
- 2014-04-15 MA MA36919A patent/MA35535B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8828989B2 (en) | 2014-09-09 |
| CR20140092A (es) | 2014-03-20 |
| NZ620653A (en) | 2016-03-31 |
| SG2014010607A (en) | 2014-05-29 |
| CN103827121A (zh) | 2014-05-28 |
| UA111623C2 (uk) | 2016-05-25 |
| MA35535B1 (fr) | 2014-10-02 |
| BR112014006945A2 (pt) | 2017-04-04 |
| CO6870036A2 (es) | 2014-02-20 |
| EA201490558A1 (ru) | 2014-06-30 |
| WO2013045373A1 (en) | 2013-04-04 |
| CA2844581A1 (en) | 2013-04-04 |
| PH12014500582A1 (en) | 2014-04-28 |
| AR087999A1 (es) | 2014-04-30 |
| AU2012314593A8 (en) | 2014-03-27 |
| TW201315737A (zh) | 2013-04-16 |
| TWI553013B (zh) | 2016-10-11 |
| US20130079333A1 (en) | 2013-03-28 |
| IN2014CN02169A (es) | 2015-05-29 |
| JP5909554B2 (ja) | 2016-04-26 |
| CL2014000717A1 (es) | 2014-10-03 |
| CN103827121B (zh) | 2016-08-03 |
| KR20140079790A (ko) | 2014-06-27 |
| EP2760871A1 (en) | 2014-08-06 |
| JP2014527993A (ja) | 2014-10-23 |
| AU2012314593A1 (en) | 2014-02-20 |
| EP2760871B1 (en) | 2018-07-18 |
| EA024990B1 (ru) | 2016-11-30 |
| PE20141397A1 (es) | 2014-10-13 |
| KR101682777B1 (ko) | 2016-12-05 |
| ECSP14013271A (es) | 2014-05-31 |
| AU2012314593B2 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12012291A (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos | |
| CO6640209A2 (es) | Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas del receptor v1a de la vasopresina | |
| ECSP12012209A (es) | HETEROBIARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS | |
| BR112012024306A2 (pt) | aril-cicloexil-tetraazabenzo[e] azulenos | |
| ECSP11011089A (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| PH12014500355A1 (en) | Lysophosphatidic acid receptor antagonists | |
| MX2014003600A (es) | Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a. | |
| BR112012025942A2 (pt) | aril-/heteroaril-ciclo-hexenil-tetra-azabenzo[e]azulenos como antagonistas de vasopressina | |
| PH12016500919A1 (en) | Spiro-oxazolones | |
| MX2016009501A (es) | Espiro-oxazolonas. | |
| MX2014003643A (es) | Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e] azulenos como antagonistas de v1a. | |
| PH12017500891A1 (en) | Spiro-thiazolones | |
| BR112015001515A2 (pt) | compostos terapêuticos |